Regeneron Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionSavant Capital, LLC
Latest Disclosed Ownership1,941 shares
Latest Disclosed Value $ 1,499,531
Savant Capital, LLC reports 5.50% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 4, 2026 - Savant Capital, LLC filed a 13F-HR form disclosing ownership of 1,941 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $1,499,694 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 2,054 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -5.50% during the quarter. The current value of the position is $1,201,382 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,941 -113 -5.50 1,500 -5.43 0.0072
2026-02-10 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,054 566 38.04 1,585 89.59 0.0090
2026-03-04 2025-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 1,488 629 73.22 837 85.78 0.0051
2025-11-05 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 5,721 4,440 3,217 0.0170
2026-03-04 2025-06-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 859 -31 -3.48 451 -20.21 0.0032
2025-08-06 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,281 -2,607 673 0.0042
2026-03-04 2025-03-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 890 -95 -9.64 565 -19.54 0.0048
2025-05-08 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,888 2,903 2,466 0.0179
2025-01-29 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 985 172 21.16 701 -17.92 0.0055
2024-11-04 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 813 189 30.29 855 30.38 0.0071
2024-08-05 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 624 75 13.66 656 24.05 0.0066
2024-05-06 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 549 35 6.81 528 17.07 0.0061
2024-02-05 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 514 117 29.47 451 38.34 0.0058
2023-11-07 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 397 26 7.01 327 22.56 0.0049
2023-08-04 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 371 5 1.37 267 -11.33 0.0042
2023-05-03 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 366 366 301 0.0056
2023-02-13 2022-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 0 -322 -100.00 0 -100.00
2023-02-06 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -322 0
2022-10-31 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 322 322 222 0.0069
2022-07-22 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -324 -100.00 0 -100.00
2022-05-05 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 324 324 226 0.0074
2020-11-04 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -360 -100.00 0 -100.00
2020-08-11 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 360 360 225 0.0170
2017-10-31 2017-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -480 -100.00 0 -100.00
2017-08-03 2017-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 480 480 236 0.0558
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.